Chariya Peeyatu

2 months ago | biorxiv.org | Lorena F Fernandes |Chariya Peeyatu |Ben Dickie |Yu Ho

AbstractResection surgery is the first-line therapy for glioblastoma (GBM) that is performed in >70% of patients, typically within days of suspected diagnosis. Current protocols for follow-on chemoradiotherapy have shown only modest efficacy in eliminating residual disease, leading to inevitable tumour recurrence. There remains a need for new approaches to swiftly and effectively treat post-operative residual disease to prevent the rapid early progression of recurrent GBM.